• ATOM study
    Categories: ,

    EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • New EORTC publications in NEJM and the Lancet Oncology

    Results of two EORTC studies have been published in NEJM and the Lancet Oncology

  • EORTC Patient recruitment Metastatic Melanoma
    Categories: ,

    EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma

  • Dr Martin Charles Mihm
    Categories: ,

    In Memoriam: Dr Martin Charles Mihm

  • Melanoma
    Categories: ,

    Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma

  • Melanoma

    PRESS RELEASE: European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients

  • Melanoma
    Categories: ,

    EORTC Melanoma Group changing daily practice for cancer patients

  • A. Eggermont - ESMO 2020

    PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma